Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P80294

UPID:
MT1H_HUMAN

ALTERNATIVE NAMES:
Metallothionein-0; Metallothionein-IH

ALTERNATIVE UPACC:
P80294; B2RUY6

BACKGROUND:
Metallothionein-1H, distinguished by its alternative names Metallothionein-0 and Metallothionein-IH, is characterized by a high cysteine content that facilitates the binding to various heavy metals. This protein's expression is influenced by both heavy metals and glucocorticoids, underscoring its pivotal role in the regulation of metal ions and protection against metal toxicity.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Metallothionein-1H offers a promising avenue for developing novel therapeutic approaches. Its critical role in metal ion regulation and detoxification processes positions it as a potential target for therapies aimed at mitigating the effects of heavy metal exposure.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.